Comparative Study of AEFI of Hepatitis B Vaccine between Iran Ministry of Health CDC and VAERS Data during 2015 to 2017
Introduction: Hepatitis B Vaccine (HBV) is a safe and effective vaccine that is nowadays recommended for all infants at birth as well as adults who could be exposed to hepatitis B virus. HBV can provide lifetime protection against hepatitis B virus infection. Despite its highly effective disease pre...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pasteur Institute of Iran
2021-06-01
|
| Series: | Vaccine Research |
| Subjects: | |
| Online Access: | http://vacres.pasteur.ac.ir/article-1-275-en.html |
| _version_ | 1818127760715939840 |
|---|---|
| author | Hamidreza Hozouri Alireza Shamsian Mohammadreza Aghasadeghi Delaram Doroud |
| author_facet | Hamidreza Hozouri Alireza Shamsian Mohammadreza Aghasadeghi Delaram Doroud |
| author_sort | Hamidreza Hozouri |
| collection | DOAJ |
| description | Introduction: Hepatitis B Vaccine (HBV) is a safe and effective vaccine that is nowadays recommended for all infants at birth as well as adults who could be exposed to hepatitis B virus. HBV can provide lifetime protection against hepatitis B virus infection. Despite its highly effective disease prevention, HBV can also cause adverse effects for the vaccinated population. A vast majority of Iran's population are vaccinated with recombinant hepatitis B vaccine (rHBV) which is manufactured by the Production and Research Complex of Pasteur Institute of Iran. Methods: The reported adverse events of rHBV, obtained from Diseases Management Center of Iran’s Ministry of Health were compared with those in The Vaccine Adverse Event Reporting System (VAERS, a United States program for vaccine safety, co-managed by the U.S. Centers for Disease Control and Prevention) during 2015 to 2017. Results: The most common adverse events after administration of rHBV, manufactured by Pasteur Institute of Iran was injection site reactions and no life threatening adverse event was observed. Conclusion: Despite reports by VAERS indicating that HBV can cause adverse events and even death in the United States, no such adverse effects were observed in rHBV manufactured in Iran. |
| first_indexed | 2024-12-11T07:22:29Z |
| format | Article |
| id | doaj.art-aec3c63e7d6b422e9050eeb100b917ed |
| institution | Directory Open Access Journal |
| issn | 2383-2819 2423-4923 |
| language | English |
| last_indexed | 2024-12-11T07:22:29Z |
| publishDate | 2021-06-01 |
| publisher | Pasteur Institute of Iran |
| record_format | Article |
| series | Vaccine Research |
| spelling | doaj.art-aec3c63e7d6b422e9050eeb100b917ed2022-12-22T01:16:03ZengPasteur Institute of IranVaccine Research2383-28192423-49232021-06-0181525910.52547/vacres.8.1.52Comparative Study of AEFI of Hepatitis B Vaccine between Iran Ministry of Health CDC and VAERS Data during 2015 to 2017Hamidreza Hozouri0https://orcid.org/0000-0002-1912-9395Alireza Shamsian 1Mohammadreza Aghasadeghi 2https://orcid.org/0000-0003-2186-0774Delaram Doroud3https://orcid.org/0000-0003-4167-9921Department of Quality Management, Pasteur Institute of Iran, Tehran, Iran. Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran.Faculty of Pharmacy, Azad University, Tehran, Iran3Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran. Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran. Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran.Introduction: Hepatitis B Vaccine (HBV) is a safe and effective vaccine that is nowadays recommended for all infants at birth as well as adults who could be exposed to hepatitis B virus. HBV can provide lifetime protection against hepatitis B virus infection. Despite its highly effective disease prevention, HBV can also cause adverse effects for the vaccinated population. A vast majority of Iran's population are vaccinated with recombinant hepatitis B vaccine (rHBV) which is manufactured by the Production and Research Complex of Pasteur Institute of Iran. Methods: The reported adverse events of rHBV, obtained from Diseases Management Center of Iran’s Ministry of Health were compared with those in The Vaccine Adverse Event Reporting System (VAERS, a United States program for vaccine safety, co-managed by the U.S. Centers for Disease Control and Prevention) during 2015 to 2017. Results: The most common adverse events after administration of rHBV, manufactured by Pasteur Institute of Iran was injection site reactions and no life threatening adverse event was observed. Conclusion: Despite reports by VAERS indicating that HBV can cause adverse events and even death in the United States, no such adverse effects were observed in rHBV manufactured in Iran.http://vacres.pasteur.ac.ir/article-1-275-en.htmlaefirhbvvaerscdcpasteur institute of iran |
| spellingShingle | Hamidreza Hozouri Alireza Shamsian Mohammadreza Aghasadeghi Delaram Doroud Comparative Study of AEFI of Hepatitis B Vaccine between Iran Ministry of Health CDC and VAERS Data during 2015 to 2017 Vaccine Research aefi rhbv vaers cdc pasteur institute of iran |
| title | Comparative Study of AEFI of Hepatitis B Vaccine between Iran Ministry of Health CDC and VAERS Data during 2015 to 2017 |
| title_full | Comparative Study of AEFI of Hepatitis B Vaccine between Iran Ministry of Health CDC and VAERS Data during 2015 to 2017 |
| title_fullStr | Comparative Study of AEFI of Hepatitis B Vaccine between Iran Ministry of Health CDC and VAERS Data during 2015 to 2017 |
| title_full_unstemmed | Comparative Study of AEFI of Hepatitis B Vaccine between Iran Ministry of Health CDC and VAERS Data during 2015 to 2017 |
| title_short | Comparative Study of AEFI of Hepatitis B Vaccine between Iran Ministry of Health CDC and VAERS Data during 2015 to 2017 |
| title_sort | comparative study of aefi of hepatitis b vaccine between iran ministry of health cdc and vaers data during 2015 to 2017 |
| topic | aefi rhbv vaers cdc pasteur institute of iran |
| url | http://vacres.pasteur.ac.ir/article-1-275-en.html |
| work_keys_str_mv | AT hamidrezahozouri comparativestudyofaefiofhepatitisbvaccinebetweeniranministryofhealthcdcandvaersdataduring2015to2017 AT alirezashamsian comparativestudyofaefiofhepatitisbvaccinebetweeniranministryofhealthcdcandvaersdataduring2015to2017 AT mohammadrezaaghasadeghi comparativestudyofaefiofhepatitisbvaccinebetweeniranministryofhealthcdcandvaersdataduring2015to2017 AT delaramdoroud comparativestudyofaefiofhepatitisbvaccinebetweeniranministryofhealthcdcandvaersdataduring2015to2017 |